Show simple item record

dc.contributor.authorCatalán Alcántara, Ana ORCID
dc.contributor.authorRichter, Anja
dc.contributor.authorSalazar de Pablo, Gonzalo ORCID
dc.contributor.authorVaquerizo Serrano, Julio
dc.contributor.authorMancebo Fernández, Gonzalo
dc.contributor.authorPedruzo, Borja
dc.contributor.authorAymerich, Claudia
dc.contributor.authorSolmi, Marco
dc.contributor.authorGonzález Torres, Miguel Ángel ORCID
dc.contributor.authorGil López, Patxi
dc.contributor.authorMcGuire, Philip
dc.contributor.authorFusar-Poli, Paolo
dc.date.accessioned2022-02-24T10:49:39Z
dc.date.available2022-02-24T10:49:39Z
dc.date.issued2021-11
dc.identifier.citationEuropean Psychiatry 64(1) : (2021) // Article ID e69es_ES
dc.identifier.issn0924-9338
dc.identifier.issn1778-3585
dc.identifier.urihttp://hdl.handle.net/10810/55564
dc.description.abstract[EN] Background To determine the proportion of patients in symptomatic remission and recovery following a first-episode of psychosis (FEP). Methods A multistep literature search using the Web of Science database, Cochrane Central Register of Reviews, Ovid/PsychINFO, and trial registries from database inception to November 5, 2020, was performed. Cohort studies and randomized control trials (RCT) investigating the proportion of remission and recovery following a FEP were included. Two independent researchers searched, following PRISMA and MOOSE guidelines and using a PROSPERO protocol. We performed meta-analyses regarding the proportion of remission/recovery (symptomatic plus functional outcomes). Heterogeneity was measured employing Q statistics and I-2 test. To identify potential predictors, meta-regression analyses were conducted, as well as qualitative reporting of studies included in a systematic review. Sensitivity analyses were performed regarding different times of follow-up and type of studies. Results One hundred articles (82 cohorts and 18 RCTs) were included in the meta-analysis. The pooled proportion of symptomatic remission was 54% (95%CI [30, 49-58]) over a mean follow-up period of 43.57 months (SD = 51.82) in 76 studies. After excluding RCT from the sample, the proportion of remission remained similar (55%). The pooled proportion of recovery was 32% (95%CI [27-36]) over a mean follow-up period of 71.85 months (SD = 73.54) in 40 studies. After excluding RCT from the sample, the recovery proportion remained the same. No significant effect of any sociodemographic or clinical predictor was found. Conclusions Half of the patients are in symptomatic remission around 4 years after the FEP, while about a third show recovery after 5.5 years.es_ES
dc.language.isoenges_ES
dc.publisherCambridge University Presses_ES
dc.rightsinfo:eu-repo/semantics/openAccesses_ES
dc.rights.urihttp://creativecommons.org/licenses/by/3.0/es/*
dc.subjectfirst-episode psychosises_ES
dc.subjectpredictorses_ES
dc.subjectpsychosises_ES
dc.subjectrecoveryes_ES
dc.subjectremissiones_ES
dc.titleProportion and predictors of remission and recovery in first-episode psychosis: Systematic review and meta-analysises_ES
dc.typeinfo:eu-repo/semantics/articlees_ES
dc.rights.holder© The Author(s), 2021. Published by Cambridge University Press on behalf of the European Psychiatric Association. This is an Open Access article, distributed under the terms of the Creative Commons Attribution licence (http://creativecommons.org/licenses/by/4.0), which permits unrestricted re-use, distribution and reproduction, provided the original article is properly cited.es_ES
dc.rights.holderAtribución 3.0 España*
dc.relation.publisherversionhttps://www.cambridge.org/core/journals/european-psychiatry/article/proportion-and-predictors-of-remission-and-recovery-in-firstepisode-psychosis-systematic-review-and-metaanalysis/E1227C06AC918471D853EF9D85AC8C0Fes_ES
dc.identifier.doi10.1192/j.eurpsy.2021.2246
dc.departamentoesNeurocienciases_ES
dc.departamentoeuNeurozientziakes_ES


Files in this item

Thumbnail
Thumbnail

This item appears in the following Collection(s)

Show simple item record

© The Author(s), 2021. Published by Cambridge
University Press on behalf of the European
Psychiatric Association. This is an Open Access
article, distributed under the terms of the
Creative Commons Attribution licence (http://creativecommons.org/licenses/by/4.0), which permits unrestricted re-use, distribution and reproduction, provided the original article is properly cited.
Except where otherwise noted, this item's license is described as © The Author(s), 2021. Published by Cambridge University Press on behalf of the European Psychiatric Association. This is an Open Access article, distributed under the terms of the Creative Commons Attribution licence (http://creativecommons.org/licenses/by/4.0), which permits unrestricted re-use, distribution and reproduction, provided the original article is properly cited.